WallStSmart

Trane Technologies plc (TT)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Trane Technologies plc generates 571% more annual revenue ($21.60B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 13.4%. TT appears more attractively valued with a PEG of 2.01. WST earns a higher WallStSmart Score of 65/100 (C+).

TT

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 4.3Quality: 6.5
Piotroski: 7/9Altman Z: 2.77

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for TT.

WSTSignificantly Overvalued (-55.4%)

Margin of Safety

-55.4%

Fair Value

$158.40

Current Price

$314.50

$156.10 premium

UndervaluedFair: $158.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TT2 strengths · Avg: 9.5/10
Return on EquityProfitability
33.6%10/10

Every $100 of equity generates 34 in profit

Market CapQuality
$104.46B9/10

Large-cap with strong market position

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

TT4 concerns · Avg: 3.5/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

EPS GrowthGrowth
-2.1%2/10

Earnings declined 2.1%

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : TT

The strongest argument for TT centers on Return on Equity, Market Cap.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : TT

The primary concerns for TT are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

TT profiles as a value stock while WST is a growth play — different risk/reward profiles.

TT carries more volatility with a beta of 1.21 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

TT generates stronger free cash flow (542M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 52/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Trane Technologies plc

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Trane Technologies plc is an American Irish domiciled diversified industrial manufacturing company. It is headquartered near Dublin, Ireland.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?